Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C
Clinical-Stage Firms Remain Private In Tough Stock Market
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.
